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Open aSummary During the H1N1 influenza pandemic (pH1N1/09) diagnostic algorithms were
developed to guide antiviral provision. However febrile illnesses are notoriously difficult to
distinguish clinically. Recent evidence highlights the importance of incorporating travel history
into diagnostic algorithms to prevent the catastrophic misdiagnosis of life-threatening infec-
tions such as malaria.
We applied retrospectively the UK pH1N1/09 case definition to a unique cohort of healthy
adult volunteers exposed to Plasmodium falciparum malaria or influenza to assess the predic-
tive value of this case definition, and to explore the distinguishing clinical features of early
phase infection with these pathogens under experimental conditions.
For influenza exposure the positive predictive value of the pH1N1/09 case definition was
only 0.38 (95% CI: 0.06e0.60), with a negative predictive value of 0.27 (95% CI: 0.02e0.51).
Interestingly, 8/11 symptomatic malaria-infected adults would have been inappropriately clas-
sified with influenza by the pH1N1/09 case definition, while 5/8 symptomatic influenza-
exposed volunteers would have been classified without influenza (P Z 0.18 Fisher’s exact).
Cough (PZ 0.005) and nasal symptoms (PZ 0.001) were the only clinical features that distin-
guished influenza-exposed from malaria-exposed volunteers.Infection Societies Conference, Edinburgh, 17the19th November 2010.
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Distinguishing malaria and influenza 193An open mind regarding the clinical cause of undifferentiated febrile illness, particularly in
the absence of upper respiratory tract symptoms, remains important even during influenza
pandemic settings. These data support incorporating travel history into pandemic algorithms.
ª 2012 Elsevier Ltd.Open access under CC BY license.Introduction
With the advent of the first pandemic of influenza of the
21st century, there was significant concern about the
potential impact on healthcare infrastructure of managing
pandemic H1N1 (pH1N1) infections in traditional settings.
In July 2009, due to sustained community transmission of
pH1N1 (with 80,000e100,000 symptomatic cases/week in
England1), control efforts shifted to mass treatment strat-
egies, and the UK National Pandemic Flu Service began to
offer treatment of symptomatic individuals identified by
telephone or internet-based triage in England.2 However
the initial pandemic influenza triage algorithm omitted
questions about travel to a malaria endemic area.3 As
a result, at least 3 cases of malaria infection in travellers
that were misdiagnosed with influenza were reported.4,5
While in a pandemic setting such triage may be essential
for efficient recognition and management of cases, the UK
case definition has been subsequently shown to be poorly
predictive.2
In the course of separate candidate vaccine efficacy
trials carried out by our unit (www.clinicaltrials.gov
NCT00890760/NCT00993083), we independently exposed
cohorts of unimmunised healthy control volunteers to
pathogenic strains of either Plasmodium falciparum (P.
falciparum) malaria or influenza A under controlled
experimental conditions, and followed them closely in the
early phases of infection until clinical diagnosis. These
control volunteers were enrolled to ensure the reliability of
the respective experimental infections and therefore did
not receive any immunisations. Although these studies were
conducted separately, assessment of clinical symptoms was
conducted according to uniform criteria. These data afford
us a unique opportunity to perform a retrospective
comparison of the early clinical features that may be of use
in differentiating clinically between an often uncompli-
cated illness in influenza and a potentially life-threatening
infection in malaria, and to assess whether the clinical
features included in the UK pandemic case definition alone
were sufficiently discriminatory.Methods
Controlled human malaria infection (CHMI)
Recruitment occurred at the Centre for Clinical Vaccinology
and Tropical Medicine, Oxford, with the challenge proce-
dure performed, using five infectious bites from P. falci-
parum 3D7-strain infected mosquitoes, at Imperial College,
London. We recruited healthy malaria naı¨ve adults aged
18e50 years old from the Oxford area. Enrolled control
volunteers (n Z 12) were seronegative for HIV, Hepatitis B
virus and Hepatitis C virus and were used to assess theinfectibility of the challenge inoculum. Routine haemato-
logical and biochemical tests on enrolled control volunteers
were all within normal limits. These control volunteers
underwent full clinical examination and safety blood tests
the day prior to sporozoite challenge. All volunteers
remained outpatients throughout the challenge procedure.
Volunteers attended twice daily for clinical assessment as
previously described.6 Self-reported solicited and unsolic-
ited symptoms and routine observations (BP, pulse,
temperature) were collected twice daily from day 6.5 post-
challenge and guided physical examination carried out as
indicated by symptoms. Thick blood films were examined
twice daily for malaria parasites by blinded microscopists
together with a concurrent highly sensitive quantitative
polymerase chain reaction (qPCR) assay for P. falciparum.
Treatment with a standard oral dose of artemether/lume-
fantrine for 3 days was administered on the detection of
a single parasite by microscopy, or on the occurrence of
significant symptoms þ sequential positive qPCR (if blood
films were negative). Volunteers were followed up daily
until two consecutive negative malaria films were
observed, and returned for full clinical assessment
including safety blood tests on days 35, 90 and 140 post-
challenge.
Controlled human influenza infection
Recruitment occurred at the Centre for Clinical Vaccinology
and Tropical Medicine, Oxford and the Wellcome Trust
Clinical Research Facility, Southampton. Volunteers aged
18e45 years were initially screened by haemagglutination
inhibition (HI) assay against the virus to be used in the
challenge phase of the study to ensure susceptibility to
challenge. Those with a titre 1:10 were eligible for
further detailed screening. Enrolled volunteers (n Z 12)
were seronegative for HIV, Hepatitis B virus and Hepatitis C
virus and had not received seasonal influenza vaccination
for at least one year prior to enrolment. Routine haema-
tological and biochemical tests on enrolled control volun-
teers were all within normal limits. Control volunteers
underwent clinical examination, spirometry, safety blood
tests and electrocardiography on entry to the quarantine
facility. Two days after entry to quarantine (to allow time
for observation of any symptoms of respiratory virus
infections) control volunteers were challenged with intra-
nasal administration of H3N2 influenza (A/Wisconsin/67/
2005) at a dose of 1 ml of 105.25 TCID50/ml. All volunteers
were inoculated during the same 2-h period. After chal-
lenge, volunteers were followed up in the quarantine
facility as previously described.7 Self-reported symptoms
were collected twice daily and a physical examination by
a blinded physician was carried out daily. Nasal lavage fluid
for quantification of viral shedding was obtained daily.
Symptoms and physician elicited clinical signs were
Table 1 Demographic details of symptomatic controlled
experimental infection volunteers.
Demographics Malaria Influenza P value
No. of volunteers 11 8 e
Median age (IQR) 28.6
(22.5e35.4)
28
(23.0e37.0)
0.51a
Male/female 6/5 3/5 0.65b
a ManneWhitney test.
b Fisher’s exact test.
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system8 (which assigns severity of symptoms such as cough,
rhinorrhoea etc., on a scale of 0e3, where no symp-
tomsZ 0; just noticeableZ 1; bothersome but can still do
activities Z 2; and bothersome and cannot do daily
activities Z 3) with a score of 4 indicating influenza
disease. Safety blood tests and further spirometry and
electrocardiography were performed on all volunteers
whilst in quarantine. A five-day course of oseltamivir was
commenced from day 5 post-challenge for all volunteers
with medication provided to complete the course after
discharge. Volunteers were released from quarantine on
the 7th day post-challenge after a negative rapid antigen
test for influenza on nasal washings was obtained. After
discharge all volunteers were followed up on days 35, 91
and 181 epost-challenge for safety blood tests.
Ethics
Clinical trial protocols (www.clinicaltrials.gov identifiers:
NCT00890760 and NCT00993083) were approved by the UK
Medicines and Healthcare Products Regulatory Agency and
the Oxfordshire NHS Research Ethics Committee. All
volunteers provided signed informed consent prior to any
study procedure, and all studies were conducted according
to the principles of Good Clinical Practice and the Decla-
ration of Helsinki.
Case definition
We examined the UK 2009 pandemic H1N1 influenza A
case definition (pH1N1/09) which was used from 2nd July
2009 to determine provision of antiviral therapy in the
absence of assessment by health professional. This was as
follows:
 Fever 38 C or history of fever,
and two or more of the following:
 Cough, sore throat, headache, rhinorrhoea, limb or
joint pain.2,9
Statistical analysis
We calculated the ability of the UK pH1N1/09 case defini-
tion to distinguish influenza-exposed unvaccinated volun-
teers from malaria-exposed unvaccinated volunteers by
calculating positive and negative predictive values. We
also analysed the significance of differences between
proportions of early symptoms in the group of malaria-
exposed and influenza-exposed volunteers, and repeated
this analysis for those individuals with laboratory-
confirmed influenza. Continuous variables were assessed
for normality and significance of differences between
central tendencies (mean or median) assessed by appro-
priate parametric or non-parametric tests (Student’s t test
or ManneWhitney U test respectively). All statistical
analysis was performed using Prism 5.0 (GraphPad), with
two-tailed tests and an alpha value of <0.05 considered
statistically significant.Results
Participants
1/12 influenza unvaccinated control volunteers developed
an asymptomatic rise in HI titre and this volunteer was
excluded prior to challenge; therefore 11 unvaccinated
controls were exposed to influenza infection. 11/12 malaria
unvaccinated control volunteers and 8/11 influenza control
volunteers subsequently developed symptoms of infection
and were included in the analysis. No serious adverse
events occurred in volunteers in either challenge. Demo-
graphic details of these participants are summarised in
Table 1. All malaria volunteers were diagnosed on the basis
of positive blood film microscopy (geometric mean para-
sitaemia 4030p/mL by qPCR) for P. falciparum a mean of
11.8 days post-challenge (Ewer K. et al., manuscript
submitted). 5/8 symptomatic influenza volunteers devel-
oped laboratory-confirmed influenza infection, defined as
positive viral culture for challenge virus on nasal lavage
fluid a mean of 2.3 days post-challenge (Lillie P.J. et al.,
Clinical Infectious Disease in press).
Predictive value of case definition
For influenza exposure the positive predictive value (PPV)
of the pH1N1/09 case definition was only 0.38 (95% CI:
0.06e0.60), with a negative predictive value (NPV) of 0.27
(95% CI: 0.02e0.51). Interestingly, 8/11 symptomatic
malaria-infected adults would have been inappropriately
classified with influenza based on the pH1N1/09 case defi-
nition, whilst for influenza only 3/8 symptomatic (PZ 0.18
Fisher’s exact) and 3/5 volunteers (P Z 1.0 Fisher’s exact)
with laboratory-confirmed influenza would have been
correctly identified.
Clinical features
Clinical features of the exposed volunteers in the influenza
and malaria cohorts are summarised in Table 2. Only the
incidence of cough (P Z 0.005 Fisher’s exact) and rhinor-
rhoea (P Z 0.001 Fisher’s exact) were significantly
different between the groups. In line with this increase in
upper respiratory tract symptoms in influenza-exposed
volunteers, there was also a trend towards an increased
frequency of sore throat (P Z 0.06 Fisher’s exact).
Restricting analysis to the 5/8 symptomatic influenza-
exposed volunteers with viral culture-confirmed infection,
Table 2 Clinical features of symptomatic individuals following pathogen exposure.
Symptom Malaria
infected (n Z 11)
Influenza
exposeda (n Z 8)
P valueb
(exposed)
Influenza
infecteda (n Z 5)
P valueb
(infected)
Cough 0 5 0.005 4 0.003
Diarrhoea 2 0 0.49 0 1.0
Headache 10 6 0.55 4 1.0
Fever 8 2 0.18 2 0.55
Malaise 3 3 1.0 2 1.0
Myalgia/arthralgia 10 5 0.72 3 0.21
Nasal symptoms 1 7 0.001 5 0.001
Nausea/vomiting 3 2 1.0 1 1.0
Sore throat 0 3 0.058 3 0.018
Met case definition 8 3 0.18 3 1.0
a 8/11 influenza-exposed volunteers became symptomatic, 5/8 of whom developed viral culture-confirmed influenza infection.
b Analysis by two-tailed Fisher’s exact test versus malaria-infected volunteers.
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and rhinorrhoea (P Z 0.001 Fisher’s exact) remained,
whilst the trend for sore throat became significant
(PZ 0.02 Fisher’s exact). Physiological parameters did not
distinguish the malaria and influenza cohorts. There were
no significant differences in the peak mean heart rate
(malaria 92.2 beats per minute [95% CI: 82.6e101.8],
influenza 82.7 [95% CI: 69.5e96.0], P Z 0.19 t test) or
temperature (malaria 37.2 C [95% CI: 36.6e37.7], influ-
enza 37.3 [95% CI: 36.9e37.7], PZ 0.72 t test) between the
groups, and there were no volunteers with clinically
significant hypotension in either group.
Laboratory features
Laboratory analysis was performed at different time-points
post-challenge for influenza and malaria-infected volun-
teers, prohibiting direct comparisons. However, grade 1
thrombocytopaenia and leucopaenia occurred with greater
frequency in malaria-exposed volunteers. The diagnosis of
malaria was confirmed by thick film microscopy in 12/12
volunteers, all of whom were also positive for P. falciparum
by qPCR. The diagnosis of influenza was confirmed by viral
culture in 5/8 symptomatic volunteers following challenge.
There were no significant abnormalities in ECG, laboratory
or spirometry parameters post-challenge in the influenza
cohort.
Discussion
The pH1N1/09 case definition was poorly predictive of
influenza infection in this cohort of unimmunised healthy
volunteers challenged with P. falciparum malaria or influ-
enza A, in keeping with recent data on its performance in
clinical practice2 as well as similar case-definitions in other
settings.10 In our studies volunteers were treated as soon as
significant symptoms or positive blood film developed,
therefore only clinical features in the early phase of illness
were addressed, and it remains possible that the power to
distinguish between these infections clinically might be
improvedwith a longer duration of illness. In addition the use
of a non-pandemic challenge strain of influenza in this studymay reduce generalisability of findings to pH1N1, which has
higher pathogenicity in younger individuals11 presumably
related to reduced pre-existing immunity12; yet all volun-
teers in our study had no detectable pre-existing immunity
to the challenge strain, so in this context they might be
considered more representative of a pandemic exposed
population. Moreover, the pre-assessment probability of
infection has a major impact on the PPV and NPV, so during
a pandemic setting (where the prevalence of influenza
would be significantly greater than malaria) the case defi-
nition would be expected to perform significantly better.
However in agreement with our data several instances of
misclassification of P. falciparum4,5 and other serious
illnesses9 have been reported in the context of protocol-
based case-definitions during the peak of community trans-
mission during the pandemic, highlighting the limitations of
such protocol or algorithm-based diagnosis.5 Telephone
consultation is an important component of infectious disease
practice,13 and telephone or internet-based triage has
considerable practical advantages in pandemic settings,
however the poor predictive capacity of the pandemic case-
definition demonstrated here supports the revisions to the
case definition to incorporate travel history.3
Only upper respiratory tract symptoms reliably distin-
guished malaria from influenza in our study. Whilst the
nasal route of inoculation may have theoretically influ-
enced the incidence of rhinorrhoea by delivering a higher
multiplicity infection to the nasal mucosa, a recent influ-
enza clinical case series identified cough as a presenting
symptom in 92% of individuals with naturally-acquired
proven influenza infection,14 suggesting that in the
absence of upper respiratory symptoms, particularly
cough,15 a presumptive diagnosis of influenza should be
reconsidered.
Phase IIa controlled experimental infection studies play
an important role in improving our understanding of the
clinical features of infectious diseases.16,17 However for
ethical reasons sample sizes for such studies are relatively
small, thus our statistical power to assess differences in
clinical features between malaria and influenza in the
analysis presented here may have been reduced. In addi-
tion, influenza challenge protocols rarely result in 100%
attack rates,7 as reflected in the 8/11 volunteers
196 P.J. Lillie et al.developing symptoms and the 5/8 symptomatic volunteers
with laboratory-confirmed influenza following nasal chal-
lenge, which further impacted sample size. Nevertheless,
several lines of evidence support the conclusion based on
these data that clinical features alone poorly distinguish
between these infections. Firstly there are no reliable
clinical diagnostic criteria for influenza.15 Secondly both
infections are frequently confused in febrile returning
travellers, where influenza is a frequent diagnosis in trav-
ellers to malaria-endemic regions,18e21 as well as in indi-
viduals in malaria-endemic regions where a significant
burden of undiagnosed influenza appears to exist in hol-
oendemic transmission settings.22 Therefore keeping an
open mind regarding the clinical cause of undifferentiated
febrile illness, particularly in the absence of upper respi-
ratory tract symptoms, remains important even during
influenza pandemic settings.
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